Becton Dickinson (BDX) EVP Garrison Discloses RSU and Performance Share Transactions

Rhea-AI Filing Summary

Becton, Dickinson and Company executive equity transaction: On 11/26/2025, EVP & President, Medical Essential & BioPharm, Michael David Garrison reported multiple equity-related transactions in Becton Dickinson & Co common stock.

He acquired 7,568 shares as restricted stock units awarded under the company’s 2004 Employee and Director Equity-Based Compensation Plan and 3,048 shares received upon vesting of performance-based equity awards, both at a price of $0 per share. In connection with these vestings, 1,769 shares were withheld to cover withholding taxes.

Following these transactions, he beneficially owned 13,734 shares of Becton Dickinson & Co common stock in direct ownership.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Garrison Michael David

Role EVP & Pres Med.Essntl&BioPharm

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,568	$0.00	--
Grant/Award	Common Stock	3,048	$0.00	--
Tax Withholding	Common Stock	1,769	$0.00	--

Holdings After Transaction: Common Stock — 12,455 shares (Direct)

Footnotes (1)

1. Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. Represents shares received upon vesting of performance-based equity awards. Represents shares withheld for payment of withholding taxes in connection with (A) the vesting of the performance units referred to in footnote (2) and (B) the vesting of restricted stock units previously reported on Table I.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garrison Michael David

(Last) (First) (Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES NJ 07417

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Pres Med.Essntl&BioPharm

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/26/2025		A		7,568(1)	A	$0	12,455	D
Common Stock	11/26/2025		A		3,048(2)	A	$0	15,503	D
Common Stock	11/26/2025		F		1,769(3)	D	$0	13,734	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

2. Represents shares received upon vesting of performance-based equity awards.

3. Represents shares withheld for payment of withholding taxes in connection with (A) the vesting of the performance units referred to in footnote (2) and (B) the vesting of restricted stock units previously reported on Table I.

Remarks:

	Donna Kalazdy, by power of attorney from Michael David Garrison	12/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Becton Dickinson (BDX) report for Michael David Garrison?

On 11/26/2025, Becton Dickinson reported that EVP & President, Medical Essential & BioPharm, Michael David Garrison acquired and had tax withholding related to equity awards in BDX common stock.

How many Becton Dickinson (BDX) shares did Michael David Garrison receive from equity awards?

Michael David Garrison received 7,568 shares from restricted stock units and 3,048 shares from the vesting of performance-based equity awards, all in Becton Dickinson common stock.

Were any Becton Dickinson (BDX) shares withheld for taxes in this Form 4 filing?

Yes. The filing shows that 1,769 shares of Becton Dickinson common stock were withheld to pay withholding taxes related to the vesting of performance units and previously reported restricted stock units.

What was Michael David Garrison’s Becton Dickinson (BDX) share ownership after the reported transactions?

After the reported transactions on 11/26/2025, Michael David Garrison beneficially owned 13,734 shares of Becton Dickinson & Co common stock in direct ownership.

What plan governed the restricted stock units reported for Becton Dickinson (BDX)?

The restricted stock units reported for Michael David Garrison were awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.

At what price were the Becton Dickinson (BDX) equity awards reported in this Form 4?

The restricted stock units and performance-based equity awards reported for Michael David Garrison were shown at a transaction price of $0 per share, as is typical for equity grants and vesting events.